{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:42:31Z","timestamp":1788838951378,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007052","name":"Universit\u00e0 degli Studi di Verona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007052","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Ocrelizumab (OCR) and Fingolimod (FGL) are two high-efficacy treatments in multiple sclerosis which, besides their strong anti-inflammatory activity, may limit neurodegeneration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aim<\/jats:title>\n                <jats:p>To compare the effect of OCR and FGL on clinical and MRI endpoints.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>95 relapsing\u2013remitting patients (57 OCR, 38 FGL) clinically followed for 36\u00a0months underwent a 3-Tesla MRI at baseline and after 24\u00a0months. The annualized relapse rate, EDSS, new cortical\/white matter lesions and regional cortical and deep grey matter volume loss were evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>OCR reduced the relapse rate from 0.48 to 0.04, FGL from 0.32 to 0.05 (both <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Compared to FGL, OCR-group experienced fewer new white matter lesions (12% vs 32%, <jats:italic>p<\/jats:italic>\u2009=\u20090.005), no differences in new cortical lesions, lower deep grey matter volume loss (\u2212\u20090.12% vs \u2212\u20090.66%; <jats:italic>p<\/jats:italic>\u2009=\u20090.002, Cohen\u2019s <jats:italic>d<\/jats:italic>\u2009=\u20090.54), lower global cortical thickness change (\u2212\u20090.45% vs \u2212\u20090.70%; <jats:italic>p<\/jats:italic>\u2009=\u20090.036; <jats:italic>d<\/jats:italic>\u2009=\u20090.42) and reduced cortical thinning\/volume loss in several regions of interests, including those of parietal gyrus (<jats:italic>d<\/jats:italic>-range\u2009=\u20090.65\u20130.71), frontal gyrus (<jats:italic>d<\/jats:italic>-range\u2009=\u20090.47\u20130.60), cingulate (<jats:italic>d<\/jats:italic>-range\u2009=\u20090.41\u20130.72), insula (<jats:italic>d<\/jats:italic>\u2009=\u20090.36), cerebellum (cortex <jats:italic>d<\/jats:italic>\u2009=\u20090.72, white matter <jats:italic>d<\/jats:italic>\u2009=\u20090.44), putamen (<jats:italic>d<\/jats:italic>\u2009=\u20090.35) and thalamus (<jats:italic>d<\/jats:italic>\u2009=\u20090.31). The effect on some regional thickness changes was confirmed in patients without focal lesions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>When compared with FGL, patients receiving OCR showed greater suppression of focal MRI lesions accumulation and lower cortical and deep grey matter volume loss.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-023-12179-y","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T08:02:59Z","timestamp":1706601779000},"page":"2149-2158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6322-9545","authenticated-orcid":false,"given":"Albulena","family":"Bajrami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Tamanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Peloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0426-7223","authenticated-orcid":false,"given":"Stefano","family":"Ziccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2341-9253","authenticated-orcid":false,"given":"Maddalena","family":"Guandalini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Calderone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1203-2670","authenticated-orcid":false,"given":"Marco","family":"Castellaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6285-0989","authenticated-orcid":false,"given":"Francesca B.","family":"Pizzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Montemezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0358-9431","authenticated-orcid":false,"given":"Damiano","family":"Marastoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3362-7403","authenticated-orcid":false,"given":"Massimiliano","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"12179_CR1","doi-asserted-by":"crossref","unstructured":"Faissner S, Plemel JR, Gold R, Yong VW (2019) Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nature Reviews Drug Discovery, vol 18","DOI":"10.1038\/s41573-019-0035-2"},{"issue":"9","key":"12179_CR2","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C et al (2020) Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol 77(9):1132\u20131140","journal-title":"JAMA Neurol"},{"issue":"3","key":"12179_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221\u2013234","journal-title":"N Engl J Med"},{"issue":"1","key":"12179_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/ana.24018","volume":"75","author":"MP Sormani","year":"2014","unstructured":"Sormani MP, Arnold DL, De Stefano N (2014) Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 75(1):43\u201349","journal-title":"Ann Neurol"},{"key":"12179_CR5","doi-asserted-by":"crossref","unstructured":"Arnold DL, Sprenger T, Bar-or A, Wolinsky JS, Kappos L, Kolind S et al (2022) Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS, pp 1\u201310","DOI":"10.1177\/13524585221097561"},{"issue":"6","key":"12179_CR6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1177\/13524585231162586","volume":"29","author":"S Kolind","year":"2023","unstructured":"Kolind S, Gaetano L, Assemlal HE, Bernasconi C, Bonati U, Elliott C, Hagenbuch N, Magon S, Arnold DL, Traboulsee A (2023) Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging. Mult Scler 29(6):741\u2013747","journal-title":"Mult Scler"},{"key":"12179_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jns.2017.10.019","volume":"383","author":"F Yousuf","year":"2017","unstructured":"Yousuf F, Dupuy SL, Tauhid S, Chu R, Kim G, Tummala S et al (2017) A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. J Neurol Sci 383:221\u2013229","journal-title":"J Neurol Sci"},{"issue":"9","key":"12179_CR8","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1007\/s00415-018-8952-2","volume":"265","author":"A Bajrami","year":"2018","unstructured":"Bajrami A, Pitteri M, Castellaro M, Pizzini F, Romualdi C, Montemezzi S et al (2018) The effect of fingolimod on focal and diffuse grey matter damage in active MS patients. J Neurol 265(9):2154\u20132161","journal-title":"J Neurol"},{"key":"12179_CR9","doi-asserted-by":"crossref","unstructured":"Pitteri M, Magliozzi R, Bajrami A, Camera V, Calabrese M (2018) Potential neuroprotective effect of Fingolimod in multiple sclerosis and its association with clinical variables, vol 19, Expert Opinion on Pharmacotherapy. Taylor and Francis Ltd, pp 387\u201395","DOI":"10.1080\/14656566.2018.1434143"},{"issue":"10127","key":"12179_CR10","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R et al (2018) Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391(10127):1263\u20131273","journal-title":"Lancet"},{"issue":"2","key":"12179_CR11","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292\u2013302","journal-title":"Ann Neurol"},{"key":"12179_CR12","doi-asserted-by":"crossref","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), pp 1444\u201353","DOI":"10.1212\/WNL.33.11.1444"},{"issue":"Issue 7 Suppl 3","key":"12179_CR13","first-page":"S3","volume":"74","author":"E Havrdova","year":"2010","unstructured":"Havrdova E, Galetta S, Stefoski D, Comi G (2010) Freedom from disease activity in multiple sclerosis. Neurology 74(Issue 7 Suppl 3):S3-7","journal-title":"Neurology"},{"issue":"4","key":"12179_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","volume":"4","author":"G Giovannoni","year":"2015","unstructured":"Giovannoni G, Turner B, Gnanapavan S, Offiah C, Schmierer K, Marta M (2015) Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord 4(4):329\u2013333","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"12179_CR15","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1212\/WNL.0b013e31820a0cc4","volume":"76","author":"JJG Geurts","year":"2011","unstructured":"Geurts JJG, Roosendaal SD, Calabrese M, Ciccarelli O, Agosta F, Chard DT et al (2011) Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology 76(5):418\u2013424","journal-title":"Neurology"},{"issue":"Pt 7","key":"12179_CR16","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1093\/brain\/awv105","volume":"138","author":"M Tintore","year":"2015","unstructured":"Tintore M, Rovira \u00c0, R\u00edo J, Otero-Romero S, Arrambide G, Tur C, Comabella M, Nos C, Ar\u00e9valo MJ, Negrotto L, Gal\u00e1n I, Vidal-Jordana A, Castill\u00f3 J, Palavra F, Simon E, Mitjana R, Auger C, Sastre-Garriga J, Montalban X (2015) Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 138(Pt 7):1863\u20131874","journal-title":"Brain"},{"issue":"4","key":"12179_CR17","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.1016\/j.neuroimage.2011.11.032","volume":"59","author":"P Schmidt","year":"2012","unstructured":"Schmidt P, Gaser C, Arsic M, Buck D, F\u00f6rschler A, Berthele A et al (2012) An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis. Neuroimage 59(4):3774\u20133783","journal-title":"Neuroimage"},{"key":"12179_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.nicl.2014.08.016","volume":"6","author":"S Valverde","year":"2014","unstructured":"Valverde S, Oliver A, Llad\u00f3 X (2014) A white matter lesion-filling approach to improve brain tissue volume measurements. NeuroImage Clin 6:86\u201392","journal-title":"NeuroImage Clin"},{"issue":"5","key":"12179_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387\u2013401","journal-title":"N Engl J Med"},{"issue":"6","key":"12179_CR20","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/ana.24651","volume":"79","author":"P Alping","year":"2016","unstructured":"Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Bj\u00f6rck A, Axelsson M, Malmestr\u00f6m C, Fink K, Lycke J, Svenningsson A, Piehl F (2016) Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol 79(6):950\u2013958. https:\/\/doi.org\/10.1002\/ana.24651","journal-title":"Ann Neurol"},{"issue":"6","key":"12179_CR21","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1007\/s00415-021-10950-7","volume":"269","author":"K Bigaut","year":"2022","unstructured":"Bigaut K, Kremer L, Fabacher T, Ahle G, Goudot M, Fleury M, Gaultier C, Courtois S, Collongues N, de Seze J (2022) Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study. J Neurol 269(6):3295\u20133300","journal-title":"J Neurol"},{"issue":"4","key":"12179_CR22","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s13311-021-01104-8","volume":"18","author":"M Cellerino","year":"2021","unstructured":"Cellerino M, Boffa G, Lapucci C, Tazza F, Sbragia E, Mancuso E, Bruschi N, Minguzzi S, Ivaldi F, Poir\u00e8 I, Laroni A, Mancardi G, Capello E, Uccelli A, Novi G, Inglese M (2021) Predictors of ocrelizumab effectiveness in patients with multiple sclerosis. Neurotherapeutics 18(4):2579\u20132588","journal-title":"Neurotherapeutics"},{"issue":"7","key":"12179_CR23","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1093\/jnen\/62.7.723","volume":"62","author":"L B\u00f8","year":"2003","unstructured":"B\u00f8 L, Vedeler CA, Nyland HI, Trapp BD, M\u00f8rk SJ (2003) Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 62(7):723\u2013732","journal-title":"J Neuropathol Exp Neurol"},{"issue":"Pt 4","key":"12179_CR24","first-page":"1089","volume":"130","author":"R Magliozzi","year":"2007","unstructured":"Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, Reynolds R, Aloisi F (2007) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early disease onset and severe cortical pathology. Brain 130(Pt 4):1089\u20131104","journal-title":"Brain"},{"issue":"9","key":"12179_CR25","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1093\/brain\/awz212","volume":"142","author":"C Elliott","year":"2019","unstructured":"Elliott C, Belachew S, Wolinsky JS, Hauser SL, Kappos L, Barkhof F, Bernasconi C, Fecker J, Model F, Wei W, Arnold DL (2019) Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain 142(9):2787\u20132799","journal-title":"Brain"},{"issue":"4","key":"12179_CR26","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/ana.25197","volume":"83","author":"R Magliozzi","year":"2018","unstructured":"Magliozzi R, Howell OW, Nicholas R, Cruciani C, Castellaro M, Romualdi C, Rossi S, Pitteri M, Benedetti MD, Gajofatto A, Pizzini FB, Montemezzi S, Rasia S, Capra R, Bertoldo A, Facchiano F, Monaco S, Reynolds R, Calabrese M (2018) Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Ann Neurol 83(4):739\u2013755","journal-title":"Ann Neurol"},{"issue":"3","key":"12179_CR27","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/ana.25786","volume":"88","author":"R Magliozzi","year":"2020","unstructured":"Magliozzi R, Scalfari A, Pisani AI, Ziccardi S, Marastoni D, Pizzini FB, Bajrami A, Tamanti A, Guandalini M, Bonomi S, Rossi S, Mazziotti V, Castellaro M, Montemezzi S, Rasia S, Capra R, Pitteri M, Romualdi C, Reynolds R, Calabrese M (2020) The CSF profile linked to cortical damage predicts multiple sclerosis activity. Ann Neurol 88(3):562\u2013573","journal-title":"Ann Neurol"},{"issue":"4","key":"12179_CR28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1177\/13524585211031786","volume":"28","author":"A Bajrami","year":"2022","unstructured":"Bajrami A, Magliozzi R, Pisani AI, Pizzini FB, Crescenzo F, Marastoni D, Calabrese M (2022) Volume changes of thalamus, hippocampus and cerebellum are associated with specific CSF profile in MS. Mult Scler 28(4):550\u2013560","journal-title":"Mult Scler"},{"issue":"3","key":"12179_CR29","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1586\/ern.10.155","volume":"11","author":"M Calabrese","year":"2011","unstructured":"Calabrese M, Rinaldi F, Grossi P, Gallo P (2011) Cortical pathology and cognitive impairment in multiple sclerosis. Expert Rev Neurother 11(3):425\u2013432","journal-title":"Expert Rev Neurother"},{"key":"12179_CR30","doi-asserted-by":"crossref","unstructured":"Benedict R, De Seze J, Hauser S, Kappos L, Wolinsky J, Zheng H et al (eds) (2018) Impact of ocrelizumab on cognition in patients at increased risk of progressive disease (P1.420). AAN","DOI":"10.1212\/WNL.90.15_supplement.P1.420"},{"key":"12179_CR31","doi-asserted-by":"crossref","unstructured":"Cohan S, Benedict R, De Seze J, Hauser S, Kappos L, Wolinsky J et al (eds) (2018) Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials (S44.005). AAN. https:\/\/n.neurology.org\/content\/90\/15_Supplement\/ S44.005 Platform Presentation S44.005. Accessed 8 Nov 2021","DOI":"10.1212\/WNL.90.15_supplement.S44.005"},{"issue":"1","key":"12179_CR32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/1352458519898108","volume":"27","author":"RH Benedict","year":"2021","unstructured":"Benedict RH, Pol J, Yasin F, Hojnacki D, Kolb C, Eckert S et al (2021) Recovery of cognitive function after relapse in multiple sclerosis. Mult Scler 27(1):71\u201378","journal-title":"Mult Scler"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-12179-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-12179-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-12179-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T07:11:46Z","timestamp":1714201906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-12179-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["12179"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-12179-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,30]]},"assertion":[{"value":"23 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AB, AT, AP, SZ, MG, MC, MC, FBP, SM have no disclosures relevant to the manuscript. DM received honoraria for research or speaking and funds for travel from Biogen Idec, Roche, Sanofi-Genzyme, Novartis. MC received honoraria for research or speaking and funds for travel from Roche, Sanofi-Genzyme, Merck Serono S.p.a Italy, Biogen Idec, Teva and Novartis.\u00a0","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The local Ethics Committee approved the present study, and informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}